BioTelemetry Inc. (NASDAQ:BEAT) hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $21.42 and last traded at $21.22, with a volume of 109,548 shares. The stock had previously closed at $21.06.

Several equities research analysts have issued reports on BEAT shares. Zacks Investment Research raised BioTelemetry from a “hold” rating to a “buy” rating and set a $23.00 price target for the company in a research note on Thursday, August 4th. Benchmark Co. lifted their price target on BioTelemetry from $20.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, August 3rd.

The firm’s 50 day moving average price is $18.94 and its 200-day moving average price is $14.83. The company has a market capitalization of $591.61 million and a P/E ratio of 44.91.

BioTelemetry (NASDAQ:BEAT) last posted its quarterly earnings data on Tuesday, August 2nd. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.17 by $0.03. The company earned $52.68 million during the quarter, compared to analysts’ expectations of $50.27 million. The company’s revenue for the quarter was up 17.6% on a year-over-year basis. During the same quarter last year, the company earned $0.12 earnings per share. On average, equities research analysts expect that BioTelemetry Inc. will post $0.76 earnings per share for the current year.

An institutional investor recently raised its position in BioTelemetry stock. Russell Frank Co increased its stake in BioTelemetry Inc. (NASDAQ:BEAT) by 58.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 249,457 shares of the company’s stock after buying an additional 92,455 shares during the period. Russell Frank Co owned approximately 0.92% of BioTelemetry worth $2,933,000 at the end of the most recent quarter.

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.